

FINAL STUDY REPORT

STUDY TITLE

Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces

Virus: Influenza B virus

DATA REQUIREMENTS

U.S. EPA 40 CFR Part 158, "Data Requirements for Registration" Pesticide Assessment Guidelines - Subdivision G, 91-2(f)

PRODUCT IDENTITY

Jymrsa A1 Batch # ATD07 + B1 Batch # BTH07 and A2 Batch # ATH07 + B2 Batch # ATH07

PROTOCOL NUMBER

WBS01101905.FLUB

PROJECT NUMBER

A03455

<u>AUTHOR</u>

Karen M. Ramm, B.A. Study Director

STUDY COMPLETION DATE

January 24, 2006

PERFORMING LABORATORY

ATS Labs 1285 Corporate Center Drive, Suite 110 Eagan, MN 55121

SPONSOR

Jymrsa, Inc. 4738 42nd Avenue N. Minneapolis, MN 55422

Page 1 of 14



STATEMENT OF NO DATA CONFIDENTIALITY CLAIMS

No claim of confidentiality is made for any information contained in this study on the basis of its falling within the scope of FIFRA Section 10 (d) (1) (A), (B), or (C).

Company: Jymrsa, Inc.

Company Agent:

Title

Date:

Signature

Jymrsa, Inc. Page 3 of 14



GOOD LABORATORY PRACTICE STATEMENT

The study referenced in this report was conducted in compliance with U.S. Environmental Protection Agency Good Laboratory Practice (GLP) regulations set forth in 40 CFR Part 160.

The studies not performed by or under the direction of ATS Labs are exempt from this Good Laboratory Practice Statement and include: characterization and stability of the test substance(s).

Submitter:

Date:_____

Sponsor:_____

Date:_____

Study Director:

Karen M. Ramm, B.A.

Date:_____



QUALITY ASSURANCE UNIT SUMMARY

Study: Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces

The objective of the Quality Assurance Unit is to monitor the conduct and reporting of non-clinical laboratory studies. These studies have been performed under Good Laboratory Practice regulations (40 CFR Part 160) and in accordance to standard operating procedures and standard protocols. The Quality Assurance Unit maintains copies of study protocols and standard operating procedures and has inspected this study on the dates listed below. Studies are inspected at time intervals to assure the integrity of the study.

Phase Inspected	Date	Study Director	Management
Critical Phase	December 29, 2005	December 29, 2005	January 24, 2006
Final Report	January 20, 2006	January 20, 2006	January 24, 2000

The findings of these inspections have been reported to management and the Study Director.

Quality Assurance Auditor:_____

Date:_____



TABLE OF CONTENTS

Title Page	1
Statement of No Data Confidentiality Claims	2
Good Laboratory Practice Statement	3
Quality Assurance Unit Summary	4
Table of Contents	5
Study Personnel	6
General Study Information	7
Test Substance Identity	7
Study Dates	7
Objective	7
Summary of Results	8
Test System	8
Methods	9
Protocol Changes	
Data Analysis	11
Study Acceptance Criteria	11
Study Retention	11
References	11
Study Results	12
Study Conclusion	12
Table 1: Virus Control and Test Results	13
Table 2: Cytotoxicity Control Results	13
Table 3: Neutralization Control Results	14

Jymrsa, Inc. Page 6 of 14



STUDY PERSONNEL

STUDY DIRECTOR:

Karen M. Ramm, B.A.

Professional Personnel Involved: Mary J. Miller, M.T. Kelleen Gutzmann, M.S. Katherine A. Paulson, M.L.T. Matthew Cantin, B.S.

- Research Scientist II
- Research Scientist II
- Research Assistant II
- Research Assistant II



STUDY REPORT

GENERAL STUDY INFORMATION

Study Title:	Virucidal Efficacy of a Disinfectant for Use on Inanimate Environmental Surfaces	
Project Number:	A03455	
Protocol Number:	WBS01101905.FLUB	
Sponsor:	Jymrsa, Inc. 4738 42nd Avenue N. Minneapolis, MN 55422	
Testing Facility:	ATS Labs 1285 Corporate Center Drive, Suite 110 Eagan, MN 55121	

TEST SUBSTANCE IDENTITY

Test Substance Name: Jymrsa Spray

Batches: A1 Batch # ATD07 + B1 Batch # BTH07 and A2 Batch # ATH07 + B2 Batch # ATH07

Test Substance Characterization

Test substance characterization as to content, stability, solubility, storage, etc., is the responsibility of the Sponsor.

STUDY DATES

Date Sample Received:	November 4, 2005
Study Initiation Date:	November 17, 2005
Experimental Start Date:	December 29, 2005
Experimental End Date:	January 5, 2006
Study Completion Date:	January 24, 2006

OBJECTIVE

The objective of this study was to evaluate the virucidal efficacy of a test substance against Influenza B virus according to test criteria and methods approved by the United States Environmental Protection Agency (U.S. EPA) for registration of a product as a virucide.



SUMMARY OF RESULTS

Test Substance:	Jymrsa, A1 Batch # ATD07 + B1 Batch # BTH07 and A2 Batch # ATH07 + B2 Batch # ATH07
Dilution:	Equal parts of A1 and B1 were mixed, and equal parts of A2 and B2 were mixed
Virus:	Influenza B virus, ATCC VR-823, Strain B/Hong Kong/5/72
Exposure Time:	Ten minutes
Exposure Temperature:	Room temperature (18-22°C)
Organic Soil Load:	5% fetal bovine serum
Efficacy Result:	Two batches of Jymrsa met the test criteria specified in the study protocol. The results indicate complete inactivation of Influenza B virus under these test conditions as required by the U.S. EPA for claims of virucidal activity.

TEST SYSTEM

1. <u>Virus</u>

The B/Hong Kong/5/72 strain of Influenza B virus used for this study was obtained from the American Type Culture Collection, Manassas, VA (ATCC VR-823). Stock virus was prepared by collecting the allantoic fluid from inoculated 11 day old fertilized, embryonated chicken eggs. The fluid was clarified by centrifugation at 1500 RPM for 10 minutes at 4°C, aliquoted and stored at \leq -70°C until the day of use. On the day of use, an aliquot of stock virus (ATS Labs Lot FB-08) was removed, thawed and refrigerated until use in the assay. The stock virus culture was adjusted to contain 5% fetal bovine serum as the organic soil load. The stock virus tested demonstrated cytopathic effects (CPE) typical of Influenza virus on Rhesus monkey kidney cells.

2. <u>Test Cell Cultures</u>

Rhesus monkey kidney (RMK) cells were obtained from ViroMed Laboratories, Inc., Cell Culture Division. The cultures were maintained and used as monolayers in disposable tissue culture labware. On the day of testing, the cells were observed as having proper cell integrity and therefore, were acceptable for use in this study.

3. Test Medium

The test medium used in this study was Minimum Essential Medium (MEM) supplemented with 1% heatinactivated fetal bovine serum (FBS), 10 μ g/mL gentamicin, 100 units/mL penicillin, and 2.5 μ g/mL amphotericin B.



The following table lists the test and control groups, the dilutions assayed, and the number of cultures used. See the report text for a more detailed explanation.

NUMBER OF DILUTIONS AND CULTURES FOR VIRUCIDAL EFFICACY STUDY			
Test or Control Group	Dilutions Assayed (log ₁₀)	Cultures per dilution	Total Cultures
Cell Control	N/A	4	4/group
Dried Virus Control (Group A)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Sample batch #1 + virus (Group B)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Sample batch #2 + virus (Group B)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Cytotoxicity of batch #1 (Group C)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Cytotoxicity of batch #2 (Group C)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Non-Virucidal level - batch #1 (Group D)	-1,-2,-3,-4,-5,-6,-7,-8	4	32
Non-Virucidal level - batch #2 (Group D)	-1,-2,-3,-4,-5,-6,-7,-8	4	32

METHODS

1. <u>Preparation of Test Substance</u>

Two batches of Jymrsa (A1 Batch # ATD07 + B1 Batch # BTH07 and A2 Batch # ATH07 + B2 Batch # ATH07) were diluted by mixing equal parts of Batch A1 and Batch B1, and mixing equal parts of Batch A2 and Batch B2. The test substances were prepared by mixing 30.0 mL of Batch A1 with 30.0 mL of Batch B1, and mixing 30.0 mL of Batch A2 with 30.0 mL of Batch B2 on the day of testing. The prepared test substances were then transferred to individual trigger spray bottles provided by the testing facility. The test substance was applied according to the use directions provided by the Sponsor. (See report section on the Treatment of Virus Films with Test Substance).

2. <u>Preparation of Virus Films</u>

Films of virus were prepared by spreading 0.2 mL of virus inoculum uniformly over the bottoms of three separate 100 x 15 mm sterile glass petri dishes. The virus films were air-dried at 19.9°C in a relative humidity of 47% until visibly dry (20 minutes).

3. <u>Sephadex Gel Filtration</u>

To reduce the cytotoxic level of the virus-test substance mixture prior to assay of virus and/or to reduce the virucidal level of the test substance, the virus was separated from test substance by filtration through Sephadex gel. Columns of Sephadex LH-20-100 were equilibrated with phosphate buffered saline containing 1% albumin and centrifuged for three minutes to clear the void volume. The columns were then ready to be used in the assay.

Jymrsa, Inc. Page 10 of 14



4. <u>Treatment of Virus Films with Test Substance</u> (GROUP B, TABLE 1)

For each batch of test substance, one dried virus film was individually exposed for ten minutes at 19.9°C to the amount of spray released under use conditions. The carriers were sprayed unitl saturated at a distance of 6-8 inches from the carrier surface. The virus films were completely covered with the test substance. Following the exposure time, the plates were individually scraped with a cell scraper to resuspend the contents and the virus-test substance mixture was immediately passed through a Sephadex column utilizing the syringe plunger in order to detoxify the mixture. The filtrate (10⁻¹ dilution) was then titered by 10-fold serial dilution and assayed for infectivity and/or cytotoxicity.

5. <u>Treatment of Virus Control Films</u> (GROUP A, TABLE 1)

A virus film was prepared as previously described (paragraph 2). The control film was exposed to 2.0 mL of test medium for ten minutes at 19.9°C. Following exposure, the virus control was scraped with a cell scraper and the virus mixture was immediately passed through a Sephadex column in the same manner as the test virus (paragraph 4). The filtrate (10⁻¹ dilution) was then titered by 10-fold serial dilution and assayed for infectivity.

6. <u>Cytotoxicity Assay</u> (GROUP C, TABLE 2)

Each batch of the test substance was sprayed as previously described onto separate sterile petri dishes. The plates were individually scraped with a cell scraper; the contents were transferred to a Sephadex column and immediately passed through the column utilizing a syringe plunger. The filtrate (10⁻¹ dilution) was then titered by 10-fold serial dilution and assayed for cytotoxicity. Cytotoxicity of the Rhesus monkey kidney cell cultures was scored at the same time as the virus-test substance and virus control cultures.

7. <u>Assay of Non-Virucidal Level of Test Substance</u> (GROUP D, TABLE 3)

Each dilution of the Sephadex-filtered test substance (cytotoxicity control) was mixed with an aliquot of low titer stock virus, and the resulting mixtures of dilutions were assayed for infectivity and/or cytotoxicity in order to determine the dilution(s) of test substance at which virucidal activity, if any, was retained. Dilutions that showed virucidal activity were not considered in determining the reduction in infectivity by the test substance.

8. <u>Infectivity Assays</u>

The RMK cell line, which exhibits CPE in the presence of Influenza B virus, was used as the indicator cell line in the infectivity assays. Cells in multiwell culture dishes were inoculated in quadruplicate with 0.1 mL of the dilutions prepared from all test and control groups. Uninfected indicator cell cultures (cell controls) were inoculated with test medium alone. The cultures were incubated at 36-38°C in a humidified atmosphere of 5-7% CO₂ in sterile disposable cell culture labware. The cultures were scored periodically for seven days for the absence or presence of CPE, cytotoxicity, and for viability.

9. <u>Statistical Methods</u>: Not applicable

PROTOCOL CHANGES

Protocol Amendments:

No protocol amendments were required for this study.

Protocol Deviation:


To assure recovery of the required minimum of four logs of infectivity from the dried virus control, the test virus utilized in the assay was propagated in fertilized, embryonated chicken eggs instead of in cell cultures as stated in the protocol. Both methods are routinely used for the propagation of Influenza B virus; therefore, in the opinion of the Study Director this protocol deviation did not impact the integrity of the assay.

Jymrsa, Inc. Page 11 of 14 **ATS LABS**

DATA ANALYSIS

Calculation of Titers

Viral and cytotoxicity titers are expressed as $-\log_{10}$ of the 50 percent titration endpoint for infectivity (TCID₅₀) or cytotoxicity (TCD₅₀), respectively, as calculated by the method of Spearman Karber.



Calculation of Log Reduction

Dried Virus Control $TCID_{50}$ – Test Substance $TCID_{50}$ = Log Reduction

STUDY ACCEPTANCE CRITERIA

A valid test requires 1) that at least 4 \log_{10} of infectivity be recovered from the dried virus control film; 2) that when cytotoxicity is evident, at least a 3-log reduction in titer is demonstrated beyond the cytotoxic level; 3) that the cell controls be negative for infectivity. **Note:** An efficacious product must demonstrate complete inactivation of the virus at all dilutions.

STUDY RETENTION

Record Retention

All of the original raw data developed exclusively for this study shall be archived at ATS Labs, 1285 Corporate Center Drive, Suite 110, Eagan, MN 55121. These original data include, but are not limited to, the following:

- 1. All handwritten raw data for control and test substances including, but not limited to notebooks, data forms and calculations.
- 2. Any protocol amendments/deviation notifications.
- 3. All measured data used in formulating the final report.
- 4. Memoranda, specifications, and other study specific correspondence relating to interpretation and evaluation of data, other than those documents contained in the final study report.
- 5. Original signed protocol.
- 6. Certified copy of final study report.
- 7. Study-specific SOP deviations made during the study.

Test Substance Retention

The test substance will be returned following study completion per Sponsor approved protocol. It is the responsibility of the Sponsor to retain a sample of the test material.

REFERENCES

- 1. Annual Book of ASTM Standards 2000, Section 11 Water and Environmental Technology Volume 11.05 Biological Effects and Environmental Fate: Biotechnology; Pesticides, E1053-97.
- 2. U.S. Environmental Protection Agency Pesticide Assessment Guidelines, Subdivision G: Product Performance, 91-2(f), November 1982.
- 3. U.S. Environmental Protection Agency, Registration Division, Office of Pesticide Programs, DIS/TSS-7, November 12, 1981.
- 4. Diagnostic Procedures for Viral, Rickettsial, and Chlamydial Infections. Schmidt, N.J. and Emmons, R.W. editors. Sixth edition, 1989. p. 18-20.
- 5. Blackwell, J.H., and J.H.S. Chen. 1970. Effects of various germicidal chemicals on HEP-2 cell culture and Herpes simplex virus. J. AOAC 53:1229-1236.

Jymrsa, Inc. Page 12 of 14



STUDY RESULTS

Results of tests with two batches of Jymrsa (equal parts of A1 Batch # ATD07 mixed with equal parts of B1 Batch # BTH07 and equal parts of A2 Batch # ATH07 mixed with equal parts of B2 Batch # ATH07), exposed to Influenza B virus in the presence of a 5% fetal bovine serum soil load at 19.9°C for ten minutes are shown in Tables 1-3. All cell controls were negative for test virus infectivity. The titer of the dried virus control was 6.0 log₁₀. Following exposure, test virus infectivity was not detected in the virus-test substance mixture for either batch at any dilution tested ($\leq 2.5 \log_{10}$). Test substance cytotoxicity was observed in both batches at 2.5 log₁₀. The neutralization control (non-virucidal level of the test substance) indicates that the test substance was neutralized at $\leq 2.5 \log_{10}$ for both batches. Taking the cytotoxicity and neutralization control results into consideration, the reduction in viral titer was $\geq 3.5 \log_{10}$ for both batches.

STUDY CONCLUSION

Under the conditions of this investigation, in the presence of a 5% fetal bovine serum soil load, Jymrsa (equal parts of A1 Batch # ATD07 mixed with equal parts of B1 Batch # BTH07 and equal parts of A2 Batch # ATH07 mixed with equal parts of B2 Batch # ATH07), demonstrated complete inactivation of Influenza B virus following a ten minute exposure time at 19.9°C as required by the U.S. EPA for virucidal label claims.

In the opinion of the Study Director, there were no circumstances that may have adversely affected the quality or integrity of the data.

The use of the ATS Labs name, logo or any other representation of ATS Labs without the written approval of ATS Labs is prohibited. In addition, ATS Labs may not be referred to in any form of promotional materials, press releases, advertising or similar materials (whether by print, broadcast, communication or electronic means) without the express written permission of ATS Labs.



TABLE 1: Virus Control and Test Results

Effects of Jymrsa (A1 Batch # ATD07 + B1 Batch # BTH07 and A2 Batch # ATH07 + B2 Batch # ATH07) Following a Ten Minute Exposure to Influenza B Virus Dried on an Inanimate Surface

Dilution	Dried Virus Control (GROUP A)	Influenza B virus + A1 Batch # ATD07 + B1 Batch # BTH07 (GROUP B)	Influenza B virus + A2 Batch # ATH07 + B2 Batch # ATH07 (GROUP B)
Cell Control	0000	0000	0000
10 ⁻¹	+ + + +	ТТТТ	ТТТТ
10 ⁻²	+ + + +	ТТТТ	ТТТТ
10 ⁻³	+ + + +	0000	0000
10 ⁻⁴	+ + + +	0000	0000
10 ⁻⁵	+ + + +	0000	0000
10 ⁻⁶	0 + 0 +	0000	0000
10 ⁻⁷	0000	0000	0000
10 ⁻⁸	0000	0000	0000
TCID ₅₀ /0.1 mL	10 ^{6.0}	≤10 ^{2.5}	≤10 ^{2.5}

TABLE 2: Cytotoxicity Control Results

Cytotoxicity of Jymrsa on Rhesus Monkey Kidney Cell Cultures

Dilution	Cytotoxicity Control A1 Batch # ATD07 + B1 Batch # BTH07 (GROUP C)	Cytotoxicity Control A2 Batch # ATH07 + B2 Batch # ATH07 (GROUP C)
Cell Control	0000	0000
10 ⁻¹	ТТТТ	ТТТТ
10 ⁻²	ТТТТ	ТТТТ
10 ⁻³	0000	0 0 0 0
10-4	0000	0 0 0 0
10 ⁻⁵	0000	0 0 0 0
10 ⁻⁶	0000	0 0 0 0
10 ⁻⁷	0000	0000
10 ⁻⁸	0000	0 0 0 0
TCD ₅₀ /0.1 mL	10 ^{2.5}	10 ^{2.5}

(+) = Positive for the presence of test virus

(0) = No test virus recovered and/or no cytotoxicity present

(T) = Cytotoxicity present



TABLE 3: Neutralization Control Results

Non-Virucidal Level of the Test Substance (Neutralization Control)

Dilution	Test Virus + Cytotoxicity Control A1 Batch # ATD07 + B1 Batch # BTH07 (GROUP D)	Test Virus + Cytotoxicity Control A2 Batch # ATH07 + B2 Batch # ATH07 (GROUP D)
Cell Control	0000	0000
10 ⁻¹	ТТТТ	ТТТТ
10 ⁻²	ТТТТ	ТТТТ
10 ⁻³	+ + + +	+ + + +
10 ⁻⁴	+ + + +	+ + + +
10 ⁻⁵	+ + + +	+ + + +
10 ⁻⁶	+ + + +	+ + + +
10 ⁻⁷	+ + + +	+ + + +
10 ⁻⁸	+ + + +	+ + + +

(+) = Positive for the presence of test virus after low titer stock virus added (neutralization control)

(0) = No test virus recovered and/or no cytotoxicity present

(T) = Cytotoxicity present

Results of the non-virucidal level control indicate that the test substance was neutralized at $TCID_{50}$ of $\leq 2.5 \log_{10}$ for both batches.